Endobarrier in diabetes with obstructive sleep apneoa
Research type
Research Study
Full title
Does treatment with Endobarrier in patients diabetes with obstructive sleep apneoa lead to improvement such that some no longer need treatemnt with an overnight CPAP (continuous positive airway pressure) machine
IRAS ID
176786
Contact name
Bob Ryder
Contact email
Sponsor organisation
Sandwell and West Birmingham Hospitals NHS Trust
Duration of Study in the UK
2 years, 5 months, 29 days
Research summary
Obstructive sleep apnea (OSA) is caused by obstruction of the upper airway. It is characterized by repetitive pauses in breathing during sleep, despite the effort to breathe, and is associated with a reduction in blood oxygen saturation. These pauses in breathing, typically last 20 to 40 seconds. Patients with OSA experience daytime sleepiness and fatigue. They are at risk of cardiovascular disease, high blood pressure, stroke, clinical depression and premature death. OSA is treated by the sufferer using a continuous positive airway pressure (CPAP) machine. During sleep, the patient wears a mask nose and mouth connected by a tube to the machine blows air into the tube to stop the hypoxia occurring. This improves the symptoms and hopefully the long term outlook, but it is not comfortable. OSA is associated with obesity. Weight loss can improve or even cure OSA. Treatment with Endobarrier can be associated with significant weight loss and can improve glycaemic control in patients with diabesity. This study aims to give Endobarrier treatment to patients with diabesity and OSA treated with CPAP, to see if the Endobarrier treatment improves the OSA to the extent that some patients no longer require their CPAP machine treatment.
REC name
East Midlands - Leicester Central Research Ethics Committee
REC reference
15/EM/0399
Date of REC Opinion
6 Oct 2015
REC opinion
Further Information Favourable Opinion